WW International, Inc. (WW)
NASDAQ (NMS) NASDAQ (NMS) Primary 
WW International, Inc. (WW) Q4 2024 Earnings Call Transcript
WW International, Inc. (NASDAQ:WW ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants David Helderman - Director, Investor Relations Tara Comonte - President & Chief Executive Officer Felicia DellaFortuna - Chief Financial Officer Donna Boyer - Chief Product Officer Conference Call Participants Nathan Feather - Morgan Stanley Michael Lasser - UBS Alex Fuhrman - Craig-Hallum Capital Group Operator Good day, and welcome to the WeightWatchers Fourth Quarter and Full Year 2024 Results Conference Call. All participants will be in a listen-only mode.
WW International (WW) Q4 Earnings and Revenues Beat Estimates
WW International (WW) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.06 per share a year ago.
WeightWatchers and lender advisors enter confidential talks for restructuring
The Wall Street Journal reported, citing unnamed sources, that WeightWatchers and the lender advisers recently entered into a confidentiality agreement.
WW International (WW) Is Attractively Priced Despite Fast-paced Momentum
WW International (WW) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
WW International Launches Next-Gen Weight Management Program
WW unveils its next-generation program, introducing advanced features aimed at transforming the weight management experience.
WW International (WW) Shows Fast-paced Momentum But Is Still a Bargain Stock
WW International (WW) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
WW International Stock Surges 67% in 3 Months: Is it Too Late to Buy?
WW's proven behavioral programs enhance its value proposition for customers seeking comprehensive weight management solutions.
More turnover at the top, but this bull still believes in the Weight Watchers parent
D.A. Davidson reckons WW is a buy as its customers need more than a prescription.
Here's Why WW International (WW) is Poised for a Turnaround After Losing -26.67% in 4 Weeks
The heavy selling pressure might have exhausted for WW International (WW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
WW International, Inc. (WW) Q3 2024 Earnings Call Transcript
WW International, Inc. (NASDAQ:WW ) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants David Helderman - Vice President, Investor Relations Tara Comonte - Interim President & Chief Executive Officer Heather Stark - Chief Financial Officer Donna Boyer - Chief Product Officer Conference Call Participants Nathan Feather - Morgan Stanley Alex Fuhrman - Craig-Hallum Capital Group Karru Martinson - Jefferies Henry Carr - UBS Operator Good day, and welcome to the WW International Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
WW International (WW) Beats Q3 Earnings and Revenue Estimates
WW International (WW) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.06 per share a year ago.
WW Stock Rises as WeightWatchers Expands Drug Offerings
Shares of WW International Inc (WW, Financial) soared by 43.09% today due to the company's strategic move to expand its clinical weight management services. This expansion includes the introduction of compounded semaglutide, which offers a cost-effective and accessible alternative to popular medications like Ozempic and Wegovy, particularly during the current supply shortages.
